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Abstract
Background:  Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia.
Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country. The first
report of CQ treatment failure in P. vivax was from Debre Zeit, which suggested the presence of
chloroquine resistance.
Methods: An in vivo drug efficacy study was conducted in Debre Zeit from June to August 2006.
Eighty-seven patients with microscopically confirmed P. vivax malaria, aged between 8 months and
52 years, were recruited and treated under supervision with CQ (25 mg/kg over three days).
Clinical and parasitological parameters were assessed during the 28 day follow-up period. CQ and
desethylchloroquine (DCQ) blood and serum concentrations were determined with high
performance liquid chromatography (HPLC) in patients who showed recurrent parasitaemia.
Results: Of the 87 patients recruited in the study, one was lost to follow-up and three were
excluded due to P. falciparum infection during follow-up. A total of 83 (95%) of the study
participants completed the follow-up. On enrolment, 39.8% had documented fever and 60.2% had
a history of fever. The geometric mean parasite density of the patients was 7045 parasites/μl.
Among these, four patients had recurrent parasitaemia on Day 28. The blood CQ plus DCQ
concentrations of these four patients were all above the minimal effective concentration (> 100 ng/
ml).
Conclusion: Chloroquine-resistant P. vivax parasites are emerging in Debre Zeit, Ethiopia. A
multi-centre national survey is needed to better understand the extent of P. vivax resistance to CQ
in Ethiopia.
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Background
Plasmodium vivax malaria is the most geographically wide-
spread and the second prevalent cause of malaria globally.
Among 2.6 billion people at risk of malaria infection,
annual estimates of P. vivax cases range from 130 to 435
million [1], 90% of these infections occur outside Africa
[2]. Ethiopia has the highest proportion of P. vivax
malaria on the continent, accounting for approximately
40% of all infection in the country [3].
Chloroquine (CQ) is the first line treatment for P. vivax
malaria in most parts of the world. However, CQ resist-
ance in P. vivax has compromised its use since the first
reported cases from Papua New Guinea in 1989 [4]. Since
then, cases of resistance have been reported from places
such as Indonesia, island of Nias, in Papua and Irian Jaya
in 1991 [5], Myanmar in 1993 and 1995 [6,7], India in
1995 [8], Borneo in 1996 [9], and in south America; Guy-
ana in 1996 [10], and parts of the Amazon Brazil [11-13],
Columbia in 2001 [14], Vietnam in 2002 [15], and Peru
in 2003 [16]. Resistance has also been reported from two
areas in Turkey in 2004 [17]. To date prevalence as high as
84% of CQ-resistant P. vivax has been reported from the
north-eastern coast of Indonesian Papua in 2003 [18].
CQ has also been the first line drug in Ethiopia for
uncomplicated malaria since 1950. Following the find-
ings of CQ treatment failure as high as 65% for P. falci-
parum in studies conducted at 18 sites between 1997/98
[19], sulphadoxine/pyrimethamine (SP) was introduced
as a first line drug treatment for uncomplicated falciparum
malaria in 1999 [20]. SP was replaced by artemether/
lumefantrine (AL) five years later after a study conducted
in 2003 in 11 sites showed 35.9% treatment failure at day
7 and 71.7% on day 28. The efficacy of AL was reported to
be 99.1% in 2004, when it replaced SP [21]. However, CQ
continued to be in use as first line drug for vivax malaria.
The first report of P. falciparun and P. vivax CQ treatment
failure in Debre Zeit, was in 1995, when only 4 of 29
(14%) P. falciparum patients cleared their asexual parasites
by day 7 and 2% of 225 P. vivax patients who were fol-
lowed for seven days failed to respond to CQ treatment
[22]. Malaria is one of the most frequently diagnosed
acute illnesses and a principal cause of morbidity affecting
all age groups in Debre Zeit. Transmission occurs
throughout the year with P. vivax being more prevalent
(70%) than P. falciparum (30%). Malaria transmission is
generally more intense following the main rainy season,
which occurs from September to December. The aim of
the present study was to determine the rate of CQ treat-
ment failure in P. vivax and confirm whether treatment




The study was conducted in Debre Zeit, the capital town
of Adea Liben district, which covers an area of approxi-
mately 1,635 km2. It is located in Oromia region (Figure
1), Central Ethiopia and is about 45 km from Addis
Ababa. An estimated population of 367,534 people live in
this area [23]. Its altitude ranges from 1,500–2,200 m asl.
It has a short rainy season from March to April and a long
rainy season from June to September. The average annual
rainfall recorded for the 10 years period (1996–2006) was
84.4 mm, while maximum and minimum temperatures
over the same period were 28.6°C and 12.9°C, respec-
tively [24].
There is one malaria centre where people with symptoms
suggestive of malaria obtain free services for malaria diag-
nosis and treatment. Recruitment and follow-up for the
present study was done at this centre.
Sample size calculation
The sample size was calculated based on the expected pro-
portion of P. vivax treatment failures with CQ in the study
population. Assuming a maximum of 5% treatment fail-
ure in a population, a precision of 5%, and a 5% signifi-
cance level, the formula, N = (Z/d)2 P (1-P) was used for
calculation. Assuming a loss-to-follow-up rate of 20%
over a 28-day study, a total of 87 study participants were
enrolled.
Patient enrolment, follow-up and treatment
Patients were recruited according to the WHO protocol for
monitoring anti-malarial drug resistance [25]. Patients
aged between eight months and 52 years with symptoms
suggestive of malaria illness, attending the malaria centre
at Debre Zeit were screened for malaria infection using
thick blood film. Those with P. vivax mono-infection with
≥250 parasites/μl of blood and elevated axillary tempera-
ture (≥37.5°C) or a history of fever within the previous 48
hours and who gave informed consent, or parent's or
guardian's consent and assent (for children aged 12–17
years) were enrolled in the study. Patients were excluded
if they had signs of severe malaria according to WHO cri-
teria [26], had another obvious cause for their fever, had a
history of allergy to CQ or lived outside the study area.
Following the treatment guidelines of the Federal Ministry
of Health of Ethiopia (FMOH), 25 mg/kg of chloroquine
phosphate (Batch Number 0073; Adigrat Pharmaceutical
Factory, Addis Ababa, Ethiopia) was administered over a
3-day period (10 mg/kg on days 0 and 1 and 5 mg/kg on
day 2) [27]. All drug doses were administered under the
supervision of a member of the research team. The study
participants were observed in case they vomited within 30
minutes of ingesting the drugs. Those who vomited theMalaria Journal 2008, 7:220 http://www.malariajournal.com/content/7/1/220
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first dose were re-treated with a similar dose, while those
who vomited twice were excluded from the study. Patients
with axillary temperatures ≥ 38°C were treated with para-
cetamol (10 mg/kg). Patients who failed to respond to CQ
treatment during the 28 days of follow-up were treated
with oral quinine (8 mg/kg per day for seven days). The
study participants were asked to return for follow-up eval-
uation on days 1, 2, 3, 7, 14, 21 and 28. Patients were
encouraged to come back to the centre if they felt ill at any
time during the follow-up period. Thick and thin blood
films were prepared at times of all follow-up visits and
additional blood samples were collected on filter paper at
day 2 and any day after day 3 when patients had shown
recurrent parasitaemia, for determination of serum CQ
and DCQ concentrations. Patients who did not return to
the malaria centre for follow-up assessment were traced to
their homes.
Treatment success was defined as clearance of parasitae-
mia with no reappearance within the 28 days of follow-up
period. Treatment failure due to CQ resistance was
defined as parasitaemia recurred during the follow-up
period in the presence of therapeutic concentrations of
CQ and DCQ (i.e ≥ 100 ng/ml as determined using
HPLC) [25,28].
The study was approved by the Addis Ababa University
Ethical Review Committee, the AHRI/ALERT Ethical
Review Committee and the National Ethical Review Com-
mittee.
Laboratory analyses
Giemsa staining of thick and thin blood film and parasite density 
determination
Thick and thin blood film slides were prepared using 10%
Giemsa solution for 30 min. The stained slides were exam-
ined under a light microscope using 100× oil immersion
by an experienced laboratory technician. Parasitaemia
was calculated per 200 white blood cells (WBC) assuming
8000 WBC/μl of blood [29]. A total of 300 fields were
Map of the study site Figure 1
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examined before a blood smear was considered negative.
Ten percent of the slides were read by a second laboratory
technician for quality control.
Drug quality assay
Drug disintegration, dissolution, identification and assay
tests were done to assess the quality of the drug used in the
study (chloroquine phosphate 250 mg containing 150 mg
of chloroquine base, Batch Number 0073, Adigrat Phar-
maceutical Factory, Addis Ababa, Ethiopia). The tested
batch of CQ tablets was determined as per the British
Pharmacopoeia (BP) [30].
Determination of CQ-DCQ concentrations on filter paper adsorbed 
blood
Blood concentrations of CQ and DCQ were measured
using the HPLC method described by Bell et al [31], with
some minor modifications for use in filter paper adsorbed
blood samples. Quinidine (internal standard; 200 ng (20
μl of 10 ng/ml solution in methanol) was added to the
blood sample spot (50 μl) adsorbed on Whatman filter
paper (17 CHR) and allowed to dry at 37°C. The filter
paper strips were cut into small pieces and put into
labelled silanized pyrex glass PTFE-lined screw-cap tubes.
Hydrochloric acid (2 M; 1 ml) was added, and the tubes
vortexed for 10 seconds. Sodium hydroxide solution (5
M; 1 ml) was added, and the tubes vortexed for 10 sec-
onds, followed by addition of the extracting solvent (tert-
butyl methyl ether: n-hexane; 5 ml). The contents were
mixed by mechanically inverting the tubes for 30 minutes
using a tube rotor (Stuart STR4 rotator drive; Stuart Scien-
tific, UK). The samples were then centrifuged (3000 rpm
for 10 min at 4°C) to separate the phases. The upper
organic phase was carefully transferred to a fresh silanized
tube and evaporated to dryness at 37°C in a water bath
under a gentle stream of white spot nitrogen gas (BOC
Kenya Ltd, Nairobi). The extracted drug was reconstituted
using mobile phase (100 μl) and an aliquot (50 μl) was
injected onto the HPLC column. The mobile phase con-
sisted of water and acetonitrile (90%: 10%; v/v) contain-
ing 1% (v/v) triethylamine, with pH adjusted to 2.8 with
orthophosphoric acid.
The chromatographic system consisted of a gradient deliv-
ery pump (Spectra System P2000, Spectra Physics Analyt-
ical Inc. CA USA) connected to a syringe loading injector
(Rheodyne Model 7125, CA USA) equipped with a 50-μl
loop. Chromatographic separation was performed using a
stainless steel analytical column (Synergi 4 μ Polar-RP
80Ä; 150 mm × 4.6 mm; Phenomenex®, Macclesfield,
Cheshire, UK), preceded by a guard column (LiChroCart
Lichrospher® RP-18e; 10 mmx 4.6 mm; 5 μm; Darmstadt,
Germany). A variable wavelength UV-visible detector
(Spectra Series® UV100; Spectra Physics Analytical Inc.,
CA, USA) set at 340 nm was used. Chromatographic data
were recorded on a ChromoJet CH1 data integrator (Spec-
tra Physics Thermo Separation Products, CA, USA).
Statistical analysis
Data was double entered using Excel 2000 and was veri-
fied using Epi info 3.4 (Centre for Disease Control and
Prevention, Atlanta, GA). STATA version 7.0 (Stat Corp.,
College station, TX, USA) was used for analysis. The sur-
vival analysis method of in vivo test was used. In this
method patients who were excluded from the study due to
P. falciparum infection or lost-to-follow-up during the
course of the project were included in the analysis as non-
treatment failure cases. Failure rate was derived from
cumulative incidence of failure at day 28. Wilcoxon rank-
sum tests were used in non-parametric comparisons, to
determine the level of significant difference, p < 0.05 was
taken as significant.
Results
Demographic and clinical characteristics of the study 
participants
A total of 2,422 consecutive patients self-reported to have
symptoms of malaria, 87 patients who satisfied the inclu-
sion/exclusion criteria were recruited. The median age of
study participants was 16 years (range: 8 months to 52
years). Twenty point seven percent (n = 18) of the study
participants were under five years of age. The mean ±
standard deviation (SD) for duration of illness was 3.15 ±
1.85 days. Among the study participants, 62.1% had a his-
tory of fever and 37.9% had documented fever at the time
of diagnosis. The geometric mean parasite density at day
0 was 6,614.6 parasites/μl (Table 1).
Symptoms such as fever, headache, chills/rigor, back pain,
vomiting, myalgia, poor appetite, abdominal pain, cough,
diarrhoea and joint pain were reported by the patients at
the time of recruitment. Among these, the major ones
were fever (96.5%), headache (86.2%) and chills/rigor
(78%). Seven percent (n = 7) of the study participants
vomited the first dose of CQ and they were retreated with
a similar dose. None of them vomited a second time.
Treatment response
Among the 87 study participants, three patients were
excluded from the study due to P. falciparum infection
during follow-up. One was found positive for asexual
stages of P. falciparum on day 21 and the other two were
positive for P. falciparum gametocytes on day 1 and 3.
Only one participant was lost to follow-up while the
remaining 83 study participants completed the 28-day fol-
low-up.
Based on therapeutic failure risk calculated by the Kaplan-
Meier survival analysis, the number of patients at risk on
day 0 was 87 and these fell to 83 at day 28. Among the 83Malaria Journal 2008, 7:220 http://www.malariajournal.com/content/7/1/220
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patients, 42% (n = 35) had cleared their parasitaemia by
day 1 and 98% (n = 81) by day 3 while 100% parasite
clearance was observed by day 7. However, 4.6% (n = 4)
of CQ treatment failure was observed during the follow-
up period. This was observed in four children below seven
years of age who developed symptomatic recurrent parasi-
taemia at day 28. This puts the risk of CQ failure on day
28 at 4.6% (Table 2).
Though the day 0 parasite density of patients with recur-
rent parasitaemia was high, the difference failed to reach
statistical significance (Wilcoxon rank sum test p = 0.061)
observed from the parasitic density observed at day 0 in
the patients who cleared their parasitaemia.
Blood concentration of CQ plus DCQ
To monitor CQ absorption, CQ plus DCQ (CQ-DCQ)
serum concentration of 83 samples (four patients with
recurrent parasitaemia and 79 patients with treatment
success) was determined on day 2. The median CQ-DCQ
concentration was 882.3 ng/ml (range: 166.8–6714.6 ng/
ml). There was no significant difference observed in the
CQ-DCQ concentration at day 2 between the patients
who showed recurrent parasitaemia and patients who had
cleared their parasitaemia within the 28 days follow-up
period (Wilcoxon rank-sum test, p = 0.52).
In order to confirm the cause of clinical treatment failure
observed in the present study, blood drug concentration
of CQ-DCQ was determined. The concentrations of CQ-
DCQ in the blood at day 28 for patients who showed
recurrent parasitaemia were all above the minimal effec-
tive concentration (MEC, 100 ng/ml) (Table 3). Further-
more, CQ and DCQ concentrations above MEC were also
measured for samples of three patients who had shown
adequate response to CQ treatment (Table 4).
PCR was run on five paired samples (four from patients
who had shown recurrent parasitaemia and one patient
who had cleared parasitaemia during the follow-up
period). However, it was only possible to amplify five iso-
lates: four day 0 samples and one day 28 sample using
primers published by Bruce et al [32]. Comparison of day
0 and day 28 samples was only possible for one patient
showing the existence of two parasite populations in
which one strain was not detected from samples that were
collected at the time of recruitment.
Discussion
According to the WHO protocol, resistance is defined as
the presentation of signs of severe malaria within the first
two days after supervised treatment or the presence of par-
asitaemia and axillary temperature > 37.5°C between day
3 and 28 or presence of parasitaemia on any day between
day 7 and day 28, irrespective of clinical conditions [25].
In addition, evidence of CQ-DCQ concentrations above
the minimal effective concentration (MEC) in the blood
demonstrates the presence of resistance regardless of the
origin of the parasite; whether it relapses from liver or is a
recrudescence from blood stage [28,33]. In line with this
definition, the present study provides evidence for the
existence of CQ resistance in P. vivax in Debre Zeit, Ethio-
pia. This was confirmed with a quantitative analysis of the
blood concentrations of CQ-DCQ, which were above
Table 1: Characteristics of patients enrolled in the in vivo efficacy 
test of chloroquine in P. vivax malaria from June-August 2006, 
Debre Zeit, Ethiopia.
Characteristics
Total number of patients recruited 87
Number of patients under the age of five 20.7% (n = 18)
Age
Median age 16 years
Range 8 Months – 52 Years
Sex
Female 41.4% (n = 36)
Male 58.8% (n = 51)
History of fever 62.1% (n = 54)
Axillary temperature > 37.5°c (day 0) 37.9% (n = 33)
Duration of illness, Mean ± SD 3.15 ± 1.85 days
Geometric mean parasite density/μl (day 0) 6,614.6 parasites
SD = standard deviation
Table 2: Estimates of risk of therapeutic failure of chloroquine in 
treatment of P. vivax, Debre Zeit, Ethiopia.
DN T F E x I R D F C I D
Day 0 87 0 0 1.000 0
Day 1 87 0 1 1.000 0
Day 2 86 0 0 1.000 0
Day 3 86 0 1 1.000 0
Day 7 85 0 1 1.000 0
Day 14 84 0 0 1.000 0
Day 21 84 0 1 1.000 0
Day 28 83 4 0 0.954 0.046
Total 4 4
D = day of test, N = number of subjects remaining at risk, TF = 
incident cases of therapeutic failure, Ex = excluded due to loss to 
follow-up, withdrawal or protocol violation, IRD = interval risk, FCID = 
cumulative incidence of therapeutic failureMalaria Journal 2008, 7:220 http://www.malariajournal.com/content/7/1/220
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MEC (100 ng/ml of blood). In addition, the presence of
CQ-DCQ concentrations on day 2 (median = 882.3 ng/
ml; range: 166.8–6714.6 ng/ml) showed that CQ was well
absorbed from the gastrointestinal tract indicating that
there were no other factors that might have influenced the
kinetics of the drug including rapid excretion or poor
absorption. Although only three samples from patients
with successful treatment response were tested, blood
concentrations of CQ-DCQ of these patients were above
the MEC, which is in accord with a previous report by
Baird et al [28].
This is the first report of CQ resistance in P. vivax from
Africa. A previous report by Tulu et al in Debre Zeit has
showed the presence of 2% (255) treatment failures in
using seven days in vivo efficacy test [20]. However, serum
drug concentrations were not determined in order to con-
firm drug resistance.
In addition to the determination of drug concentrations
in patient blood samples, molecular genotyping is recom-
mended in studies of anti-malarial drug efficacy [25]. This
method is used to distinguish between relapse/recrudes-
cence and re-infection in P. vivax. In present study, msp 3-
alpha was used to genotype P. vivax isolates from patients
who showed parasitaemia. The primers failed to amplify
parasite isolates which could be due to the mismatch at
the 3' end of the primers, thus not attached to the parasite
DNA which, lead to an inconclusive result for the geno-
type. One limitation of this study is that it did not explore
other marker genes, including Pvcsp and Pvmsp1, which
had been applied elsewhere for genotyping in P. vivax par-
asite isolates to obtain additional information on the
diversity of the resistant isolates [34].
Though genotyping is recommended in differentiating
relapse/recrudescence and re-infection, it has shortcom-
ings when used for P. vivax as this method assumes that
the primary parasite population is the same as in recurrent
parasitaemia due to relapse [35]. However, recent studies
from three different countries have shown the presence of
heterologous hypnozoites in the liver [36] in which a sin-
gle allelic type of hypnozoite is being activated at a time
[37], thus leading to misclassification of a recrudescence
as a new infection. In addition, this assumption does not
take into account the possibility of few strains circulating
at low parasite density that cannot be detected in primary
samples but could emerge to cause treatment failure,
which again leads to misclassification of the treatment
response [33]. Moreover, lack of a standardized classifica-
tion of the outcome in categorizing mixed genotypes as
recrudescence or re-infection is another limitation of this
method. Therefore, in order to detect the emergence of
drug resistance in P. vivax, clinical follow-up in combina-
Table 3: Chloroquine (CQ) plus desethylchloroquine (DCQ) concentration in the blood of P. vivax malaria patients with recurrent 
parasitaemia, Debre Zeit, Ethiopia, 2006.
Blood CQ+DCQ concentration (ng/ml)
Case No Age (years) Day 2 Day 28
02 2.4 829.9 524.6
37 7 486.1 672.1
57 3.4 1557.8 868.6
84 5 1611.9 1164.0
Table 4: Chloroquine (CQ) plus desethylchloroquine (DCQ) concentration in the blood of P. vivax malaria patients who have adequate 
clinical and parasitological response, Debre Zeit, 2006.
Blood CQ+DCQ concentration (ng/ml)
Case No Age (years) Day 2 Day 28
61 2.7 759.8 218.4
79 5 816.6 297.3
46 8 1,447.1 521.8Malaria Journal 2008, 7:220 http://www.malariajournal.com/content/7/1/220
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tion with determination of CQ-DCQ concentrations in
the blood at a time of recurrent parasitaemia will give a
definitive diagnosis rather than follow-up in combination
with genotyping. Since mixed parasite strains were
observed in day 28 samples, when compared to day 0
sample, it was difficult to categorize as recrudescence/
relapse from new infection.
In Ethiopia, there is a surveillance system for assessing the
efficacy of first line drug for the treatment of P. falciparum.
However, there have been no systematic studies for P.
vivax. The present data confirmed the emergence CQ
resistant P. vivax in the Debre Zeit. Even though the level
of resistance is not so high as to require a treatment policy
change, the finding will be useful in alerting the responsi-
ble authorities to monitor the level of drug resistance and
to determine the extent of this problem in all parts of the
country, bearing in mind that P. vivax malaria is responsi-
ble for 40% of malaria cases in Ethiopia.
Conclusion
Chloroquine-resistant P. vivax parasites are emerging in
Debre Zeit, Ethiopia. There is a need for regular monitor-
ing of the pattern of resistance to antimalarial drugs in the
country.
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